home / stock / aezs / aezs news

AEZS News and Press, Aeterna Zentaris Inc. From 06/21/22

Stock Information
Company Name: Aeterna Zentaris Inc.
Stock Symbol: AEZS
Market: NASDAQ
Website: zentaris.com
Menu
AEZS AEZS Quote AEZS Short AEZS News AEZS Articles AEZS Message Board
Get AEZS Alerts

News, Short Squeeze, Breakout and More Instantly...
AEZS - Aeterna Zentaris Announces Results of Annual Meeting of Shareholders

- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna " or the " Company "), a specialty biopharmaceutical company developing and commercializing a d...
AEZS - AEterna Zentaris (AEZS) Investor Presentation - Slideshow

The following slide deck was published by Aeterna Zentaris Inc. in conjunction with this event. For further details see: AEterna Zentaris (AEZS) Investor Presentation - Slideshow

AEZS - Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program

– Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD") – Positive r esults presented at the 13 th International Congress ...

AEZS - Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference

Live vid eo webcast on Wednesday, June 15 th at 12:30 PM ET TORONTO, ONTARIO, June 09, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company de...
AEZS - Aeterna Zentaris licensing partner Consilient launches growth hormone deficiency test in Europe

Aeterna Zentaris (NASDAQ:AEZS) said its licensing partner Consilient Health launched Ghryvelin, an oral test for diagnosing growth hormone deficiency in adults, in Europe. The company said Ghryvelin  (macimorelin) was approved in European in 2019, backed by data ...

AEZS - Aeterna Zentaris' Licensing Partner, Consilient Health Announces European Launch of Ghryvelin(TM) (macimorelin) for Diagnosing Adult Growth Hormone Deficiency

TORONTO, ONTARIO, May 25, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic pro...

AEZS - Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference

TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic pro...
AEZS - Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation

TORONTO, ON, May 16, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ” or the “ Company ”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced th...

AEZS - Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson's Disease

– Data presented at IMMUNOLOGY2022 ™ , the A nnual Event of the American Association of Immunologists – Company advancing development of its Autoimmunity Modifying ( “ AIM &#x...

AEZS - Aeterna Zentaris GAAP EPS of -$0.02, revenue of $1.5M

Aeterna Zentaris press release (NASDAQ:AEZS): Q1 GAAP EPS of -$0.02. Revenue of $1.5M (-11.8% Y/Y). The company ended the quarter with $63.6M in cash, expected to fund operations through 2023. For further details see: Aeterna Zentaris GAAP EPS of -$0.0...
Previous 10 Next 10